{"id":"lantus-glargine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glargine is a recombinant human insulin analog engineered with amino acid substitutions to delay absorption and provide a relatively constant insulin level over 24 hours. It mimics the body's basal insulin secretion, allowing cells to take up glucose from the bloodstream and reducing hepatic glucose production. This sustained action helps maintain glycemic control in diabetic patients.","oneSentence":"Lantus is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:24.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT07461103","phase":"PHASE2","title":"Effect of Topical Insulin on Healing Rate of Pemphigus Lesions","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-22","conditions":"Pemphigus Vulgaris, Skin Erosion, Autoimmune Blistering Disease","enrollment":20},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT05803421","phase":"PHASE3","title":"A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-03","conditions":"Type 2 Diabetes, Obesity, Overweight or Obesity","enrollment":2749},{"nctId":"NCT06716424","phase":"PHASE4","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-06","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT07076199","phase":"PHASE3","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":877},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT07307235","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-15","conditions":"Type 2 Diabetes","enrollment":1316},{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT04460885","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-25","conditions":"Diabetes Mellitus, Type 2","enrollment":984},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT07171684","phase":"NA","title":"Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-11-26","conditions":"Diabetes in Pregnancy, Gestational Diabetes","enrollment":176},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT06767735","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-17","conditions":"Diabetes","enrollment":580},{"nctId":"NCT06767761","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-18","conditions":"Diabetes","enrollment":580},{"nctId":"NCT05514535","phase":"PHASE3","title":"A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-29","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":568},{"nctId":"NCT06688123","phase":"PHASE2","title":"Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-01-08","conditions":"Type 2 Diabetes","enrollment":275},{"nctId":"NCT07224893","phase":"PHASE4","title":"Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management","status":"NOT_YET_RECRUITING","sponsor":"Eastern Virginia Medical School","startDate":"2025-12-01","conditions":"Pregestational Diabetes, Pregnancy","enrollment":200},{"nctId":"NCT06109311","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-11-10","conditions":"Type 2 Diabetes","enrollment":546},{"nctId":"NCT06370715","phase":"PHASE4","title":"A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-18","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05002933","phase":"PHASE4","title":"A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-05-20","conditions":"Type 2 Diabetes Mellitus","enrollment":570},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT07117240","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Warsaw","startDate":"2025-07-10","conditions":"Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes","enrollment":100},{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT05114590","phase":"PHASE4","title":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-01-27","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT06340854","phase":"PHASE3","title":"A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-19","conditions":"Diabetes, Type 2","enrollment":429},{"nctId":"NCT06269107","phase":"PHASE3","title":"A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Type 2 Diabetes","enrollment":485},{"nctId":"NCT05662332","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-01-14","conditions":"Type 2 Diabetes, T2D","enrollment":795},{"nctId":"NCT05098470","phase":"PHASE3","title":"Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-03-07","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT06717191","phase":"PHASE4","title":"Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-09","conditions":"Type 1 Diabetes","enrollment":296},{"nctId":"NCT07070752","phase":"PHASE3","title":"Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-04-14","conditions":"Type 1 Diabetes Mellitis","enrollment":224},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06627478","phase":"PHASE1","title":"Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®","status":"COMPLETED","sponsor":"Xentria, Inc.","startDate":"2024-10-29","conditions":"Healthy Participants","enrollment":114},{"nctId":"NCT05922033","phase":"PHASE4","title":"Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2023-10-19","conditions":"Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk","enrollment":56},{"nctId":"NCT06999551","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.","status":"NOT_YET_RECRUITING","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2025-07-01","conditions":"Diabetes Mellitus","enrollment":60},{"nctId":"NCT05780151","phase":"PHASE4","title":"Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)","status":"COMPLETED","sponsor":"Mira Zuidgeest","startDate":"2023-07-10","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT05702073","phase":"PHASE3","title":"To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-31","conditions":"Type 2 Diabetes Mellitus","enrollment":423},{"nctId":"NCT03723772","phase":"PHASE1","title":"A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 1","enrollment":66},{"nctId":"NCT05699408","phase":"PHASE3","title":"To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-31","conditions":"Type 2 Diabetes","enrollment":513},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT06419803","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT06419777","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT06674135","phase":"PHASE4","title":"Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-01","conditions":"Type I Diabetes","enrollment":202},{"nctId":"NCT06624943","phase":"PHASE4","title":"Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-03-14","conditions":"Type 1 Diabetes (T1D)","enrollment":260},{"nctId":"NCT06487598","phase":"NA","title":"To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hirabai Cowasji Jehangir Medical Research Institute","startDate":"2024-07-01","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT06619301","phase":"PHASE3","title":"RCT Glargine vs NPH for Treatment of DM in Pregnancy","status":"RECRUITING","sponsor":"Loyola University","startDate":"2024-04-01","conditions":"Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2","enrollment":160},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT00708981","phase":"NA","title":"Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2007-05","conditions":"Diabetic Nephropathy","enrollment":120},{"nctId":"NCT06178874","phase":"NA","title":"Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-12-01","conditions":"Glycemic Control, Insulin, Critical Illness","enrollment":90},{"nctId":"NCT06007508","phase":"PHASE2","title":"Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"HealthPartners Institute","startDate":"2022-05-31","conditions":"DKA","enrollment":8},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT03437330","phase":"PHASE4","title":"Empagliflozin Effect on Glucose Toxicity","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-10-27","conditions":"Type2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03371082","phase":"PHASE3","title":"Gan & Lee Insulin Glargine Target Type (1) Evaluating Research","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2017-10-31","conditions":"Diabetes Mellitus, Type 1","enrollment":576},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT05607160","phase":"","title":"A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-10-05","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":82},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT04623086","phase":"PHASE4","title":"Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-02-14","conditions":"Type 1 Diabetes","enrollment":59},{"nctId":"NCT03455985","phase":"NA","title":"Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low","enrollment":158},{"nctId":"NCT04153981","phase":"PHASE4","title":"A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":304},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT04575181","phase":"PHASE1","title":"A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-21","conditions":"Diabetes Mellitus, Type 2","enrollment":86},{"nctId":"NCT05596747","phase":"PHASE1","title":"A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT02491528","phase":"PHASE3","title":"A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2015-06-19","conditions":"Diabetes","enrollment":563},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT06127433","phase":"PHASE4","title":"The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-07","conditions":"Insulin Pump，Continuous Glucose Monitoring Technology","enrollment":210},{"nctId":"NCT00313742","phase":"PHASE4","title":"The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":51},{"nctId":"NCT00687453","phase":"PHASE4","title":"Insulin Glargine Versus Twice-Daily NPH","status":"TERMINATED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2003-02","conditions":"Type 2 Diabetes Mellitus","enrollment":27},{"nctId":"NCT04537923","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-19","conditions":"Type 2 Diabetes","enrollment":1428},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT05373186","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT02408120","phase":"PHASE4","title":"Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT05579119","phase":"PHASE4","title":"SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)","status":"COMPLETED","sponsor":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social","startDate":"2022-07-06","conditions":"Type 2 Diabetes","enrollment":76},{"nctId":"NCT05373199","phase":"PHASE1","title":"A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT06007014","phase":"NA","title":"Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2023-10-31","conditions":"Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients, Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect, 128 Patients Were Randomly Assigned 1:1","enrollment":128},{"nctId":"NCT03945656","phase":"PHASE1","title":"A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-07","conditions":"Diabetes Mellitus, Type 2","enrollment":43},{"nctId":"NCT00357890","phase":"NA","title":"Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2005-12","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":12},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT04591626","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT01779375","phase":"PHASE3","title":"RISE Pediatric Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-06-16","conditions":"Prediabetes, Type 2 Diabetes","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3460,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lantus (glargine): Sanolfi Aventis","NPH: Eli Lilly"],"phase":"phase_3","status":"active","brandName":"Lantus (glargine)","genericName":"Lantus (glargine)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lantus is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}